| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/21/2006 | EP1671650A1 Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
| 06/21/2006 | EP1671649A1 Remedy for diabetes |
| 06/21/2006 | EP1671647A1 Medicament for treating cancer |
| 06/21/2006 | EP1671644A2 Pharmaceutical compositions containing Lysostaphin alone or in combination with an antibiiotic for the treatment of Staphylococcal infections |
| 06/21/2006 | EP1671643A1 Medicinal composition for treating chronic hepatitis c |
| 06/21/2006 | EP1671639A1 Treatment of acquired immunedeficiency syndrome AIDS with a combination therapy including curdlan sulphate |
| 06/21/2006 | EP1671638A1 Disphosphonate solutions |
| 06/21/2006 | EP1671637A2 Treatment of diabetes with thiazolidinedione and sulphonylurea |
| 06/21/2006 | EP1671636A1 5-aminosalicylic acid solid preparation improved in discoloration and method of storing the same |
| 06/21/2006 | EP1671635A1 Noncrystalline antibacterial composition containing cefditoren pivoxil |
| 06/21/2006 | EP1671634A1 Small organic molecule regulators of cell proliferation |
| 06/21/2006 | EP1671633A1 Use of PPAR agonists for the treatment of congestive heart failure |
| 06/21/2006 | EP1671632A1 Pharmaceutical combination of angiotensin II antagonists and ACE inhibitors |
| 06/21/2006 | EP1671631A2 Compositions for the treatment of chronic lymphocytic leukemia |
| 06/21/2006 | EP1671630A2 L-Arginine based formulations for treating diseases and methods of using the same |
| 06/21/2006 | EP1671629A1 Human beta-defensin secretion promoter |
| 06/21/2006 | EP1671628A1 Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction |
| 06/21/2006 | EP1671627A1 Methods for improving cell therapy and tissue regeneration in patients with cardiovascular and neurological diseases by means of shockwaves |
| 06/21/2006 | EP1671626A1 Transdermal patch comprising progesteron A specific ligands (PRASL) as active agent |
| 06/21/2006 | EP1671625A1 Nanoparticles |
| 06/21/2006 | EP1671624A1 Delivery device for a controlled drug release of an active agent into the posterior section of the eye |
| 06/21/2006 | EP1671623A1 Composition for use in the antibacterial and antiinflammatory treatment of the oral cavity |
| 06/21/2006 | EP1671618A1 Composition for promoting collagen production |
| 06/21/2006 | EP1671549A2 Method for enhancing exercise performance and recovery |
| 06/21/2006 | EP1671541A1 Disinfectant |
| 06/21/2006 | EP1671129A1 Compounds and methods for promoting angiogenesis by using a gamma-secretase inhibitor or inhibiting the gamma-secretase pathway |
| 06/21/2006 | EP1670915A2 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 06/21/2006 | EP1670902A2 METHOD AND COMPOSITION FOR ENHANCING i IN VITRO /i EMBRYO DEVELOPMENT BY SUPPLEMENTING CULTURE MEDIUM WITH PROSTAGLANDIN OR A PROSTAGLANDIN ANALOG |
| 06/21/2006 | EP1670896A2 Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry |
| 06/21/2006 | EP1670838A1 Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery |
| 06/21/2006 | EP1670812A2 Ozonation products of cholesterol for the treatment and prevention of atherosclerosis and/or cardiovascular diseases |
| 06/21/2006 | EP1670810A2 Gapped oligomeric compounds having linked bicycli csugar moieties at the termini |
| 06/21/2006 | EP1670809A2 Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives |
| 06/21/2006 | EP1670808A1 Antimicrobial derivatives |
| 06/21/2006 | EP1670804A2 Heterobicyclic compounds as pharmaceutically active agents |
| 06/21/2006 | EP1670802A2 Novel heterocyclic compounds as hsp90-inhibitors |
| 06/21/2006 | EP1670795A1 Pharmacologically active imidazo 4,5-c pyridines |
| 06/21/2006 | EP1670794A2 Vanilloid receptor ligands and their use in treatments |
| 06/21/2006 | EP1670793A1 Antibacterial agents |
| 06/21/2006 | EP1670791A2 Thiophene-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| 06/21/2006 | EP1670790A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| 06/21/2006 | EP1670787A2 Cytokine inhibitors |
| 06/21/2006 | EP1670786A1 Quinazoline derivatives |
| 06/21/2006 | EP1670782A1 Quinazoline derivatives |
| 06/21/2006 | EP1670780A2 Compounds and compositions as protein kinase inhibitors |
| 06/21/2006 | EP1670777A1 Use of 8-prenylnaringenin for hormone replacement therapy |
| 06/21/2006 | EP1670775A1 Piperazine subtituted compounds used as calcium channel blockers |
| 06/21/2006 | EP1670771A1 Compounds and compositions as protein kinase inhibitors |
| 06/21/2006 | EP1670770A1 Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof |
| 06/21/2006 | EP1670769A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| 06/21/2006 | EP1670760A1 Organic compounds |
| 06/21/2006 | EP1670758A1 Substituted indole acid derivatives and their use as pai-1 inhibitors |
| 06/21/2006 | EP1670739A2 Cyclic diamines and derivatives as factor xa inhibitors |
| 06/21/2006 | EP1670718A2 Subtituted fullerene compositions and their use as antioxydants |
| 06/21/2006 | EP1670551A1 Combination of phenylcarboxamides with beta-adrenergic receptor blockers and use thereof for the treatment of atrial arrhythmias |
| 06/21/2006 | EP1670514A2 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor |
| 06/21/2006 | EP1670513A2 Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy |
| 06/21/2006 | EP1670508A2 Compositions, methods and kits relating to poxvirus subunit vaccines |
| 06/21/2006 | EP1670502A2 Oligopeptides as coating material for medical products |
| 06/21/2006 | EP1670500A2 Compositions capable of facilitating penetration across a biological barrier |
| 06/21/2006 | EP1670491A2 Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
| 06/21/2006 | EP1670490A1 Method for inhibiting bacterial colonisation |
| 06/21/2006 | EP1670487A1 Therapeutic formulations |
| 06/21/2006 | EP1670486A1 Treatment of a condition in a mammal with adminisration of aminosugar and uses thereof |
| 06/21/2006 | EP1670485A1 Treatment of diseases associated with the egr-1 enhancer element |
| 06/21/2006 | EP1670484A1 Nitric oxide donating derivatives for the treatment of cardiovascular disorders |
| 06/21/2006 | EP1670483A1 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
| 06/21/2006 | EP1670482A1 Use of ciclesonide for the treatment of respiratory diseases |
| 06/21/2006 | EP1670481A1 Use of ciclesonide for the treatment of inflammatory bowel diseases |
| 06/21/2006 | EP1670480A2 Use of steroids to treat ocular disorders |
| 06/21/2006 | EP1670479A1 The combination of a serotonin reuptake inhibitor and amoxapine |
| 06/21/2006 | EP1670478A2 Heteroaromatic selective inhibitors of neuronal nitric oxide synthase |
| 06/21/2006 | EP1670477A2 Combinations of drugs for the treatment of neoplasms |
| 06/21/2006 | EP1670476A2 Phenyl pyrrolidine ether tachykinin receptor antagonists |
| 06/21/2006 | EP1670475A2 Alaphatic pyrazinoylguanidine sodium channel blockers |
| 06/21/2006 | EP1670474A2 Cyclic pyrazinoylguanidine sodium channel blockers |
| 06/21/2006 | EP1670472A1 Aerosol formulation for inhalation, containing an anticholinergic agent |
| 06/21/2006 | EP1670471A1 Treatment of neurological disorders related to rapid eye movement (rem) sleep disturbances with npy y5 receptor antagonists |
| 06/21/2006 | EP1670470A1 Pyridine derivatives and use thereof as urotensin ii antagonists |
| 06/21/2006 | EP1670469A1 Use of known active ingredients as radical scavengers |
| 06/21/2006 | EP1670468A1 Use of npy y5 receptor antagonist for the treatment of circadian rhythm disorders |
| 06/21/2006 | EP1670467A1 Methods and compositions for the oral administration of prodrugs of proton pump inhibitors |
| 06/21/2006 | EP1670466A2 Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors |
| 06/21/2006 | EP1670465A1 Ocular solutions containing a macrolide antibiotic and/or mycophenolic acid |
| 06/21/2006 | EP1670464A1 Topical compositions comprising telmesteine for treating dermatological disorders |
| 06/21/2006 | EP1670463A2 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
| 06/21/2006 | EP1670462A1 Combination therapy for hcv infection |
| 06/21/2006 | EP1670459A2 Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use |
| 06/21/2006 | EP1670458A1 1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, methods for the production thereof, and their use as antiphlogistics |
| 06/21/2006 | EP1670457A1 Bicycl 3.1.1]heptane substituted benzimidazolone and quinazolinone derivatives as agonists on human orl1 receptors |
| 06/21/2006 | EP1670456A2 Compounds, compositions and methods |
| 06/21/2006 | EP1670455A2 Treatment of diseases involving erbb2 kinase overexpression |
| 06/21/2006 | EP1670454A1 The combination of a serotonin reuptake inhibitor and loxapine |
| 06/21/2006 | EP1670453A2 Amino acid based compositions for the treatment of pathological conditions distinguished by insufficient mitochondrial function |
| 06/21/2006 | EP1670452A2 Method of use of aminoacids having affinity for the a2d protein |
| 06/21/2006 | EP1670451A1 Treating and/or preventing urinary incontinence using prodrugs of gaba analogs |
| 06/21/2006 | EP1670450A2 Pharmaceutical compositions and method of using levodopa and carbidopa |
| 06/21/2006 | EP1670449A2 Thyroid hormone analogs and methods of use in angiogenesis |
| 06/21/2006 | EP1670448A1 Hcv inhibitiing sulfonamides |
| 06/21/2006 | EP1670447A1 Modafinil modified release pharmaceutical compositions |